Kojun Okamoto
Overview
Explore the profile of Kojun Okamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishida M, Okamoto K, Koyama I, Uchida N, Sato I, Yoshioka A, et al.
Palliat Support Care
. 2025 Mar;
23:e64.
PMID: 40079075
Objectives: Naldemedine is a peripherally acting μ-opioid receptor antagonist used to treat opioid-induced constipation. As this drug does not cross the blood-brain barrier, it is believed that patients without brain...
2.
Oshima Y, Watanabe Y, Kato T, Takase K, Watanabe Y, Okada K, et al.
Gan To Kagaku Ryoho
. 2025 Feb;
51(13):1724-1727.
PMID: 39948979
In this report, we described a case of an extremely rare primary neuroendocrine tumor of the gallbladder, which corresponds to NET G1 according to the WHO classification. The patient was...
3.
Watanabe Y, Aikawa M, Murase Y, Oshima Y, Kato T, Takase K, et al.
Gan To Kagaku Ryoho
. 2025 Feb;
51(13):1678-1680.
PMID: 39948964
It is unclear whether the remnant stomach can be safely preserved, performing distal pancreatectomy in patients with a prior distal gastrectomy. A 74-year-old man was followed up after robotic distal...
4.
Todo M, Shirotake S, Kaneko G, Okamoto K, Sugasawa M, Nakahira M, et al.
In Vivo
. 2024 Dec;
39(1):440-451.
PMID: 39740869
Background/aim: Measures to control adverse events (AEs) in the use of oral multi-kinase inhibitors (OMI) are important for the continuation of treatment. Patients And Methods: In this study, oncology pharmacists...
5.
Kato T, Watanabe Y, Baba Y, Oshima Y, Takase K, Watanabe Y, et al.
Surgery
. 2024 Oct;
178():108845.
PMID: 39384476
Background: Several risk-stratified studies have compared the outcomes of external and internal pancreatic stents in pancreatoduodenectomy (PD), but no resolute standard for a fistula-mitigation strategy exists. The study investigated the...
6.
Kato T, Okada K, Baba Y, Yasuda M, Ohshima Y, Takase K, et al.
Eur J Surg Oncol
. 2024 Oct;
50(12):108691.
PMID: 39366161
Background: Patients with distal cholangiocarcinoma (DCC) frequently receive adjuvant chemotherapy in preoperative and postoperative settings, but prediction of prognostic risk at the time of treatment selection remains challenging. Methods: This...
7.
Kato T, Watanabe Y, Oshima Y, Takase K, Watanabe Y, Okada K, et al.
Surgery
. 2024 Jun;
176(3):880-889.
PMID: 38879380
Background: An increasing number of patients are achieving long-term survival after pancreatoduodenectomy, meaning that risk assessments of endocrine and exocrine pancreatic insufficiency are needed. Herein, we investigated the risk factors...
8.
Watanabe Y, Aikawa M, Oshima Y, Kato T, Takase K, Watanabe Y, et al.
Surg Endosc
. 2024 Jun;
38(7):3887-3904.
PMID: 38831217
Background: Laparoscopic liver resection (LLR) is rapidly gaining popularity; however, its efficacy for nonalcoholic fatty liver disease (NAFLD)-associated hepatocellular carcinoma (HCC) (NAFLD-HCC) has been not evaluated. The purpose of this...
9.
Hozaka Y, Ohtsuka T, Nakamura M, Hijioka S, Unno M, Shimizu Y, et al.
Pancreas
. 2023 Nov;
52(5):e288-e292.
PMID: 37922344
Objective: We aimed to elucidate the feasibility of surveillance of patients with mucinous cystic neoplasm (MCN). Methods: We performed a retrospective, multi-institutional study of 328 patients who underwent surgery for...
10.
Watanabe Y, Aikawa M, Oshima Y, Kato T, Takase K, Watanabe Y, et al.
HPB (Oxford)
. 2023 Sep;
25(12):1573-1586.
PMID: 37758580
Background: We compared the recurrence-free survival (RFS), overall survival (OS), and safety of laparoscopic liver resection (LLR) between non-alcoholic fatty liver disease (NAFLD) and non-NAFLD hepatocellular carcinoma (HCC) patients. Methods:...